Dreesen D W, Bernard K W, Parker R A, Deutsch A J, Brown J
Vaccine. 1986 Mar;4(1):45-9. doi: 10.1016/0264-410x(86)90096-4.
Following a routine 0.1 ml booster dose of Merieux rabies human diploid cell vaccine (HDCV), administered intradermally, 23(10.2%) of 226 persons had signs and symptoms compatible with an immune complex-like disease. The disease had its onset from 3-13 days after the injection, lasted 1-5 days, and consisted primarily of urticaria (78.3%), macular rash (65.2%), angiooedema (39.1%), and arthralgia (17.4%). None of the cases were considered severe, and all recovered with no sequelae. There were significant differences in attack rates between men (78.3% of all cases) and women, and between those receiving vaccinations on different days. Similar reactions have been reported following intramuscular booster doses of HDCV. Since the Merieux HDCV is used worldwide, physicians administering HDCV must be aware of these adverse reactions and warn patients. Appropriate therapy should be instituted as warranted by severity of reactions.
在皮内注射0.1毫升常规的梅里埃狂犬病人类二倍体细胞疫苗（HDCV）加强剂量后，226人中的23人（10.2%）出现了与免疫复合物样疾病相符的体征和症状。该疾病在注射后3至13天发病，持续1至5天，主要表现为荨麻疹（78.3%）、斑疹（65.2%）、血管性水肿（39.1%）和关节痛（17.4%）。所有病例均不被认为严重，且全部康复，无后遗症。男性（占所有病例的78.3%）和女性之间以及在不同日期接种疫苗的人群之间的发病率存在显著差异。肌肉注射HDCV加强剂量后也报告了类似反应。由于梅里埃HDCV在全球范围内使用，使用HDCV的医生必须了解这些不良反应并警告患者。应根据反应的严重程度进行适当治疗。
